IMM News: Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data - 19th May 2023, 2:42am

[annb0t]

Shares of Immutep Limited IMMP surged 64.8% on May 17, after it announced positive data from part A of the phase II TACTI-002 study that evaluated the combination use of its lead pipeline candidate, eftilagimod alpha (“efti”) in first-line (“1L”) non-small cell lung cancer (“NSCLC”).

Part A of the TACTI-002 study, which evaluated the combination of efti and Merck‘s MRK blockbuster anti-PD-1 therapy Keytruda (pembrolizumab), achieved robust initial overall surv...

>>> Read more: Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data